Monoclonal antibodies against checkpoint molecules such as programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) have yielded unprecedent success in CRC patients (9, 10). The gene discussed is CD274; the disease is colorectal carcinoma.